Novel colchicine derivatives and their anti-cancer activity

Lorelei Johnson, Ing Swie Goping, Aja Rieger, Jonathan Y. Mane, Torin Huzil, Asok Banerjee, Richard Luduena, Bashar Hassani, Philip Winter, Jack A. Tuszynski

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


In this paper we provide an overview of the status of various colchicine derivatives in preclinical development with special focus on their anti-cancer activity. We discuss several groups of compounds that have been designed to differentially bind with specific affinities for tubulin β isotypes, especially in regard to βIII, which is commonly over-expressed in cancer. Computational prediction, protein-based and cell-based assays are summarized as well as some animal tests conducted on these compounds. It is concluded that an untapped potential exists for exploiting the colchicine scaffold as a pharmacophore with the possibility of increasing its affinity for tubulin isotypes over-expressed in cancer and decreasing it for normal cells thereby widening the therapeutic window.

Original languageEnglish (US)
Pages (from-to)2538-2558
Number of pages21
JournalCurrent topics in medicinal chemistry
Issue number22
StatePublished - Sep 1 2017


  • Animal tests
  • Anti-cancer
  • Colchicine Scaffold
  • Pharmacophore
  • Tubulin β isotypes

ASJC Scopus subject areas

  • Drug Discovery


Dive into the research topics of 'Novel colchicine derivatives and their anti-cancer activity'. Together they form a unique fingerprint.

Cite this